Shares of Gland Pharma Limited rose over 9% on Thursday with the stock trading at Rs 1763.80 apiece. This comes after the pharmaceutical company in Mumbai declared their Q3 earnings on Wednesday.
The company’s revenue grew 22.5% to Rs 1,695 crore, compared with Rs 1,384 crore in the previous year. Net profit increased by 27.7%, reaching Rs 262 crore versus Rs 205 crore year‑on‑year. The EBITDA rose 20.8% to Rs 435 crore, up from Rs 360 crore a year earlier. The EBITDA margin stood at 25.6%, slightly lower than 26% in the previous year.
Gland Pharma Q3 Highlights (YoY)
- Revenue rises 22.5% to Rs 1,695 crore versus Rs 1,384 crore.
- Net Profit up 27.7% at Rs 262 crore versus Rs 205 crore.
- Ebitda rises 20.8% to Rs 435 crore versus Rs 360 crore.
- Ebitda Margin at 25.6% versus 26%.
Gland Pharma’s was started in 1978 as a contract manufacturer of small-volume liquid parenteral products in Hyderabad. Over the years, it has evolved into one of the largest and fastest-growing generic injectables manufacturing companies, with a global presence spanning 60 countries, including the US, Europe, Canada, Australia, and India.
Gland Pharma Share Price Today
Gland Pharma Share Price Today
Photo Credit: (Photo: NDTV Profit)
The scrip rose as much as 9.32% to Rs 1763.80 apiece on Tuesday. This compares to a 0.68% decline in the NSE Nifty 50 Index.
Total traded volume so far in the day stood at 0.12 times its 30-day average. The relative strength index was at 49.35.
Out of 18 analysts tracking the company, 11 maintain a ‘buy’ rating, two recommend a ‘hold,’ and five suggest ‘sell,’ according to Bloomberg data. The average 12-month consensus price target of Rs 2016.00 implies an upside of 13.5%.
ALSO READ: Sun Pharma, Cipla Recall Products In US: FDA
Watch LIVE TV, Get Stock Market Updates,
Top Business, IPO and
Latest News on NDTV Profit.
